149 related articles for article (PubMed ID: 27896820)
1. PPARγ targeted oral cancer treatment and additional utility of genomics analytic techniques.
Handley N; Eide J; Taylor R; Wuertz B; Gaffney P; Ondrey F
Laryngoscope; 2017 Apr; 127(4):E124-E131. PubMed ID: 27896820
[TBL] [Abstract][Full Text] [Related]
2. PPARγ in head and neck cancer prevention.
Burotto M; Szabo E
Oral Oncol; 2014 Oct; 50(10):924-9. PubMed ID: 24434068
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of PPARgamma activation by the oral antidiabetic agent pioglitazone in Barrett's carcinoma in vitro and in vivo.
Al-Taie OH; Graf T; Illert B; Katzenberger T; Mörk H; Kraus MR; Barthelmes HU; Scheurlen M; Seufert J
J Gastroenterol; 2009; 44(9):919-29. PubMed ID: 19506796
[TBL] [Abstract][Full Text] [Related]
4. Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ.
McCormick DL; Horn TL; Johnson WD; Peng X; Lubet RA; Steele VE
PLoS One; 2015; 10(10):e0141849. PubMed ID: 26516762
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evidence for pioglitazone and bexarotene combination in oral cancer chemoprevention.
Rosas RR; Nachbor KM; Handley N; Mathison G; Wuertz BR; Ba'th F; Ondrey FG
Head Neck; 2022 Mar; 44(3):661-671. PubMed ID: 34931381
[TBL] [Abstract][Full Text] [Related]
6. Functional activation of PPARγ in human upper aerodigestive cancer cell lines.
Wright SK; Wuertz BR; Harris G; Abu Ghazallah R; Miller WA; Gaffney PM; Ondrey FG
Mol Carcinog; 2017 Jan; 56(1):149-162. PubMed ID: 26999671
[TBL] [Abstract][Full Text] [Related]
7. Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner.
Richard CL; Blay J
Int J Oncol; 2007 May; 30(5):1215-22. PubMed ID: 17390024
[TBL] [Abstract][Full Text] [Related]
8. The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves nitric oxide availability, renin-angiotensin system and aberrant redox regulation in the kidney of pre-hypertensive rats.
Kvandova M; Barancik M; Balis P; Puzserova A; Majzunova M; Dovinova I
J Physiol Pharmacol; 2018 Apr; 69(2):. PubMed ID: 29980143
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment.
Grommes C; Landreth GE; Sastre M; Beck M; Feinstein DL; Jacobs AH; Schlegel U; Heneka MT
Mol Pharmacol; 2006 Nov; 70(5):1524-33. PubMed ID: 16887936
[TBL] [Abstract][Full Text] [Related]
10. G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY.
Wang S; Awad KS; Elinoff JM; Dougherty EJ; Ferreyra GA; Wang JY; Cai R; Sun J; Ptasinska A; Danner RL
J Biol Chem; 2015 Aug; 290(32):19544-57. PubMed ID: 26105050
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone prevents smoking carcinogen-induced lung tumor development in mice.
Li MY; Kong AW; Yuan H; Ma LT; Hsin MK; Wan IY; Underwood MJ; Chen GG
Curr Cancer Drug Targets; 2012 Jul; 12(6):597-606. PubMed ID: 22463586
[TBL] [Abstract][Full Text] [Related]
12. FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators.
Fujimura T; Sakuma H; Konishi S; Oe T; Hosogai N; Kimura C; Aramori I; Mutoh S
J Pharmacol Sci; 2005 Dec; 99(4):342-52. PubMed ID: 16314690
[TBL] [Abstract][Full Text] [Related]
13. PPARγ-Mediated p21 Induction in Aerodigestive Preneoplastic Cell Lines.
Miller WA; Wuertz BR; Ondrey FG
Ann Otol Rhinol Laryngol; 2018 Oct; 127(10):677-686. PubMed ID: 30047791
[TBL] [Abstract][Full Text] [Related]
14. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients.
Klotz L; Schmidt M; Giese T; Sastre M; Knolle P; Klockgether T; Heneka MT
J Immunol; 2005 Oct; 175(8):4948-55. PubMed ID: 16210596
[TBL] [Abstract][Full Text] [Related]
15. Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.
Al-Alem L; Southard RC; Kilgore MW; Curry TE
PLoS One; 2011 Jan; 6(1):e16179. PubMed ID: 21283708
[TBL] [Abstract][Full Text] [Related]
16. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.
Rasouli N; Kern PA; Elbein SC; Sharma NK; Das SK
Pharmacogenet Genomics; 2012 Jul; 22(7):484-97. PubMed ID: 22437669
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes.
Namvaran F; Azarpira N; Rahimi-Moghaddam P; Dabbaghmanesh MH
Eur J Pharmacol; 2011 Dec; 671(1-3):1-6. PubMed ID: 21968139
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production.
Uruno A; Matsuda K; Noguchi N; Yoshikawa T; Kudo M; Satoh F; Rainey WE; Hui XG; Akahira J; Nakamura Y; Sasano H; Okamoto H; Ito S; Sugawara A
J Mol Endocrinol; 2011 Feb; 46(1):37-49. PubMed ID: 21106862
[TBL] [Abstract][Full Text] [Related]
19. Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC.
Ciaramella V; Sasso FC; Di Liello R; Corte CMD; Barra G; Viscardi G; Esposito G; Sparano F; Troiani T; Martinelli E; Orditura M; De Vita F; Ciardiello F; Morgillo F
J Exp Clin Cancer Res; 2019 Apr; 38(1):178. PubMed ID: 31027492
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPAR{gamma}.
Subramanian V; Golledge J; Ijaz T; Bruemmer D; Daugherty A
Circ Res; 2010 Oct; 107(8):953-8. PubMed ID: 20798360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
